Cat. No. 5513
Alternative Names: 13-cis-retinoic acid, Accutane
Chemical Name: 13-cis-Retinoic acid
Biological ActivityEndogenous agonist for retinoic acid receptors. Promotes neurite outgrowth, cell differentiation and inhibits proliferation in a neuroblastoma cell line. Also increases protein expression levels of MYCN and retinoic acid receptor-β. Anti-inflammatory.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Sonawane et al (2014) Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br.J.Pharmacol. 171 5330. PMID: 25039756.
Diamandis et al (2007) Chemical genetics reveals a complex functional ground state of neural stem cells. Nat.Chem.Biol. 3 268. PMID: 17417631.
Blaner et al (2001) Cellular metabolism and actions of 13-cis-retinoic acid. J.Am.Acad.Dermatol. 45 S129. PMID: 11606944.
If you know of a relevant reference for Isotretinoin please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Isotretinoin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Isotretinoin, supplier, Endogenous, agonists, retinoic, acid, receptors, neuronal, differentiation, anti-inflammatory, RAR, Retinoic, Acid, Receptors, RXR, Retinoid, X, Tocris Bioscience, Retinoic Acid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic progesterone analogC-DIM 12
Nurr1 activator; inhibits NF-κB-dependent gene expression(S)-Equol
Potent estrogen receptor β (ERβ) agonistAilanthone
Potent inhibitor of androgen receptor (AR)(±)-ML 209
RORγt inverse agonist; suppresses Th17 cell differentiationAGN 193109
High affinity pan-RAR antagonistSR 9243
Selective LXR inverse agonist
June 14 - 17, 2017
Boston, MA, USA